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V itamin D is essential for the maintenance of musculoskeletal health through the regu-lation of calcium and phosphate homeostasis. Severe prolonged deficiency of vitamin D
can lead to rickets in children and osteomalacia in adults. Both conditions are now rare in
the UK, except in high-risk groups such as those with malabsorption and reduced exposure
to sunlight. A much more common situation is ‘biochemical’ vitamin D deficiency, where
circulating 25(OH)D concentrations fall below pre-defined thresholds in the absence of
osteomalacia or rickets, making vitamin D deficiency and insufficiency very common in
the UK particularly during the winter months and early spring. Biochemical vitamin D
deficiency has been associated with various non-skeletal disorders, but it seems likely
that the low vitamin D levels in these situations are the result of the underlying condition,
rather than the cause.
Clinical case scenario
Carolyn, a 47-year-old female, comes to see you with a 1-year history of generalised aching, particularly of her lower back,
thighs, hips and feet, a non-specific feeling of reduced well-being and ‘weakness’ of her arms and legs. She rarely attends the
GP clinic, having not ventured out of her house for many years due to agoraphobia. She now walks to the local shop and GP
clinic, but for short visits only. For many years she used illicit drugs and when she achieved abstinence became a vegan. She
continues to adhere strictly to this diet. Apart from a brief stay in a drug rehabilitation centre 15 years ago, she has no other
past medical history and is not on regular or over-the-counter medication.
On examination she walks independently with a normal gait. Her body mass index (BMI) is 19.3 kg/m2. Cardiovascular,
respiratory and gastrointestinal systems appear normal. Generalised tenderness is evident on palpation over her lower back,
hips, pelvis, thighs and feet. Tone, power and reflexes are normal at all four limbs.
Bloods tests are arranged and you conclude that osteomalacia secondary to vitamin D deficiency is the most likely cause
of her symptoms based on her clinical presentation, presence of risk factors (strict adherence to a vegan diet and lack of
sunlight exposure) and blood biochemistry results (low vitamin D and raised alkaline phosphate and parathyroid hormone).
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You recommend 10 000 IU of vitamin D daily, but she is very wary and wants to know if this supplement is derived from
animal products. You reassure her that you can prescribe a vegan-friendly product. You discuss the importance of increasing
sunlight exposure and she agrees to sit at her patio occasionally. Repeat blood tests at 1 month show normal phosphate and
calcium. Alkaline phosphatase (ALP) has risen to 250 u/L, which is consistent with healing osteomalacia. At four months
25(OH)D and parathyroid hormone (PTH) levels are normal. You reduce the dose of vitamin D to 800 IU daily and advise
continuing this life-long. Eight months after starting treatment her symptoms have resolved.
Vitamin D physiology
Vitamin D is a fat-soluble vitamin. Around 70% comes from
sunlight exposure where 7-dehyrocholesterol in the skin is
converted by the action of ultraviolet light into cholecalciferol
(vitamin D3) (Firth et al., 2020). The remaining 30% is derived
by dietary intake of both ergocalciferol (vitamin D2) and chole-
calciferol. Cholecalciferol undergoes 25-hydroxylation in the
liver, resulting in the production of calcidiol (25-hydroxyvita-
min D or 25(OH)D). This is a biologically inactive metabolite,
but is the one that is measured in vitamin D assays; 25(OH)D is
present at nanomolar concentrations (106 molar) in the blood.
A further hydroxylation step occurs in the kidneys through the
action of 1-alpha-hydroxylase to produce calcitriol
(1,25(OH)2D), the metabolically active form of vitamin D,
which is present in picomolar (109 molar) concentrations in
the blood (Firth et al., 2020; Hobson et al., 2018).
Currently, serum 25(OH)D levels below 25 nmol/L are
considered consistent with vitamin D deficiency, whereas
‘insufficiency’ is the term used to describe the situation
where values lie between 25 and 50 nmol/L. Calcitriol
increases intestinal absorption of calcium and phosphate
and regulates differentiation of osteoblasts (bone-forming
cells) and osteoclasts (bone-resorbing cells). Synthesis of
calcitriol is tightly regulated PTH and fibroblast growth
factor 23 (FGF23). PTH is produced by the parathyroid
glands in response to lowered blood calcium concentrations.
The increased levels of PTH help to maintain serum calcium
values within the normal range by increasing calcium
reabsorption by the renal tubule and by promoting calcitriol
synthesis. FGF23 is produced by osteocytes; it plays a major
role in promoting phosphate excretion by the kidney by
acting on the renal tubule and also suppresses calcitriol
production by the kidney. Many inherited forms of rickets
and osteomalacia are caused by genetic mutations that
increase circulating levels of FGF23 (Hobson et al., 2018).
Figure 1 provides a visual representation of vitamin D
metabolism.
Figure 1. Pathway of vitamin D production.
Reprinted by permission from Springer Nature, Calcified Tissue International, Vitamin D Assays: Past and Present Debates, Difficulties, and
Developments, Fraser WD, Milan AM, 92, 118–127 (2013).
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Sources of vitamin D
Biochemical vitamin D deficiency is common in the UK popu-
lation, due to its northerly position. Latitude and season affect
the quantity and quality of solar radiation reaching the Earth.
In people located in the UK, there is very little synthesis of
cholecalciferol from sunlight between October and March, but
thereafter synthesis increases reaching a peak in September
after exposure during the summer months. Many factors
including degree of skin pigmentation, time of day, season,
latitude, use of sunscreens and social circumstances influence
the length of time that an individual is exposed to sunlight,
which in turn influences vitamin D production. The National
Institute for Health and Care Excellence (NICE) recommend
that people are encouraged to spend at least two short periods
per week from April to October in direct sunlight exposing
their legs, arms and face or to consider taking foods or dietary
supplements such as cod-liver oil oil that are rich in vitamin D.
It is, however, essential to remember the risk of skin cancer
from excessive exposure to sunlight (NICE, 2018).
The most common sources of dietary vitamin D include
oily fish, red meat, liver and egg yolks. Milk and dairy products
in the UK are relatively poor sources of vitamin D because
they are not routinely fortified. In the UK, all margarine sold
for domestic use was fortified on a mandatory basis between
1940 and 2013. Voluntary fortification continues in many fat
spreads, breakfast cereals, and dried milk. EU Law safeguards
ensure mandatory fortification of infant formula (Scientific
Advisory Committee on Nutrition (SACN), 2016).
Risk factors for vitamin D deficiency
It is important to consider vitamin D status in people at all ages
and stages of life, ranging from before birth until old age. Infants
are dependent on vitamin D reserves built up throughout
pregnancy and via intake of milk and food. Direct exposure
to sunlight is not recommended for infants younger than 1
year of age, so sunlight cannot be relied upon. Breastmilk is
not a significant source of vitamin D, so infants who are exclu-
sively breastfed or taking <500 mls of infant formula daily are
potentially at risk of deficiency (NICE, 2014). Vitamin D status
in infants is proportionate to maternal reserves; therefore,
exclusively breastfed infants of mothers with untreated osteo-
malacia are at particularly high risk of vitamin D deficiency and
hypocalcaemia (Hatun et al., 2005). Maternal osteomalacia is
often asymptomatic, making it important to be aware of risk
factors for vitamin D deficiency when considering health pro-
motion discussions with pregnant women. See Table 1 for
details of risk factors for vitamin D deficiency.
People with darker skin are more likely to have low vitamin
D status, as they require longer exposure of their skin to the
sun to produce the same amount of vitamin D as people with
paler skin (NICE, 2014). In addition, people of African descent
may have low 25(OH)D levels in the absence of true defi-
ciency of vitamin D, due to genetic variations in the level of
vitamin D binding protein (Powe et al., 2013). Older, frail,
hospitalised or imprisoned people are at increased risk, as
they are more likely to spend time indoors with less exposure
to sunlight (Macdonald et al., 2011; NICE, 2014).
It is important to think about the need for a discussion
around vitamin D-related health in people with risk factors.
These discussions can take place as health promotion during
a routine GP consultation and it is in this context that you can
actively promote good health and prevent future complications.
Clinical consequences of vitamin D
deficiency
In the majority of cases, vitamin D deficiency is asymptomatic
(Hobson et al., 2018; NICE, 2018). Severe and prolonged
Table 1. Risk factors for vitamin D deficiency.
Risk factor Details
Reduced sunlight exposure Low or no exposure to the sun, the covering of skin for religious or cultural reasons,
excessive use of sunscreen over SPF 15
Reduced oral intake Infrequent consumption of fish products, eggs, red meat and liver, vegetarian and
vegan diets
Reduced intestinal absorption Malabsorption syndromes, short bowel syndrome, cholestatic liver disease, gastric
bypass surgery
Obesity BMI >30 kg/m2
Medications Certain anticonvulsants, highly active antiretrovirals, glucocorticoids, cholestyramine,
rifampicin
Genetics Genetic variation of the vitamin D binding protein and other genes involved in vitamin
D metabolism
Pregnancy Particularly those with multiple short interval pregnancy or those exclusively breast-
feeding without oral vitamin D supplementations
Source: Francis et al. (2018); Liu et al. (2018); Information (2020); Excellence (2014); Hatun et al. (2005); Pereira-Santos et al. (2015); Pearce and
Cheetham (2010); NICE (2018).
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deficiency of vitamin D results in rickets in children and osteo-
malacia in adults. It is important to remember that there is no
single threshold for serum 25(OH)D that is diagnostic of either
disorder and large scale studies have shown that most people,
even with very low 25(OH)D levels, do not have evidence of
impaired mineralisation of bone on histological analysis of
bone biopsies (Priemel et al., 2010).
Osteomalacia and rickets are most commonly linked to
inadequate exposure to sunlight. Malabsorption syndromes
can predispose to deficiency through reduced absorption of
vitamin D and calcium. Loss of 1,25-hydroxylation can occur
secondary to chronic renal failure. Osteomalacia and rickets
can also arise as the result of inherited disorders of renal phos-
phate reabsorption, which are typically associated with raised
FGF23 levels and mutations in the vitamin D receptor or the
genes involved in converting 25(OH)D to 1,25(OH)2D3
(Hobson et al., 2018).
Rickets
Rickets leads to softening of the bones, which then become
prone to deformity and fractures. Skeletal features include pro-
gressive bowing of the legs and knock-knees, softening of
skull bones and frontal bossing, delayed eruption of teeth
and enamel hypoplasia, and growth plate enlargement seen
as wrist swelling and rachitic rosary (swollen costochondral
junctions at the chest wall). Skeletal deformities can present
as early as 6 months of age (Wharton and Bishop, 2003).
Muscle weakness can present as difficulty climbing stairs, wad-
dling gait and difficulty rising from a seated position. Vitamin
D deficiency rickets usually presents after 6 months of age on
depletion of intrapartum reserves, and is associated with
weakness, drowsiness, tetany and seizures (Hobson et al.,
2018). Older children can be affected by bone pain, short
stature, a tendency to lower respiratory tract infections sec-
ondary to a compliant chest wall and muscle weakness,
chest pain and skeletal deformities such as scoliosis (Pearce
and Cheetham, 2010).
Osteomalacia
In adults the most common complication of severe vitamin D
deficiency is osteomalacia. Osteomalacia is characterised by
impaired mineralisation of bone. When vitamin D deficiency is
severe and prolonged, PTH levels become chronically ele-
vated in an attempt to maintain serum calcium values within
the normal range (secondary hyperparathyroidism). The ele-
vated PTH levels increase osteoclastic bone resorption,
increased calcium reabsorption from the renal tubules and
promote phosphate excretion. If 25(OH)D deficiency persists,
there is a gradual failure of 1,25(OH)D production, resulting in
defective absorption of calcium and phosphate from the gut.
Eventually this leads to demineralisation of bone, which is the
defining feature of osteomalacia (Bordelon et al., 2009).
Osteomalacia presents with weakness at the pelvic girdle mus-
cles in up to 30% of people, resulting in difficulties rising to
stand and walking often mobilising with a waddling gait (Firth
et al., 2020; Sievenpiper et al., 2008). Muscle tenderness on
pressure and focal bone pain can arise secondary to fissure
fractures at the ribs and pelvis (Hobson et al., 2018). In older
adults, vitamin D-related orthostatic hypotension can result in
a greater risk of falls, institutionalisation, and death (Duval
et al., 2015).
Generalised bone pain can be mistaken for fibromyalgia or
somatisation of depression (Firth et al., 2020; Hobson et al.,
2018; Sievenpiper et al., 2008). It is important to bear this in
mind when seeing people with long-standing chronic pain
issues, as misdiagnosis can lead to years of preventable suf-
fering and disability. Having said that, many people with fibro-
myalgia and chronic pain have low vitamin D levels as a
consequence of their health condition, due to poor diet and
limited sunlight exposure, rather than it being the cause of
their symptoms.
Non-skeletal conditions
There is much current debate around potential associations
between low circulating vitamin D levels and various diseases
including most types of cancer, chronic kidney disease, hyper-
tension, diabetes, multiple sclerosis, chronic inflammatory dis-
eases, age-related macular degeneration, depression,
psychosis and all-cause mortality (Hobson et al., 2018).
Reverse causality could be responsible where these conditions
have predisposed people to lower vitamin D status secondary
to less sunlight exposure and poor diet (Hobson et al., 2018;
SACN, 2016). Awareness of this debate can be useful when
you are asked about the significance of low vitamin D status.
Investigations
There is no universal consensus of what is optimal vitamin D
status, as many people with vitamin D ‘deficiency’ or ‘insuffi-
ciency’ are in perfectly good health (Aspray et al., 2014).
Therefore, it is important to be mindful of the need to
reduce unnecessary healthcare costs, prescribing and resultant
anxiety caused by performing a vitamin D level only when it is
clinically indicated (Pilz et al., 2019). Figure 2 provides a visual
illustration of the clinical significance of vitamin D deficiency
by clinical group.
Where testing is appropriate, serum 25(OH)D is the recom-
mended test. It closely measures uptake from the diet and
sunlight and has a half-life of 2 to 3 weeks (Aspray et al.,
2014; Firth et al., 2020; NICE, 2018). If vitamin D levels are
low, serum PTH, serum calcium, phosphate and ALP are
useful investigations to help determine if the low 25(OH)D
is of clinical significance. People with osteomalacia and rickets
always have secondary hyperparathyroidism and usually have
raised ALP values. Serum calcium and phosphate values tend
to be low, but can be in the normal range. It is important to
remenber that a low 25(OH)D value can occur due to genetic
variations in the levels of vitamin D binding protein in the
absence of physiological vitamin D deficiency.
There has been a substantial increase in requests for meas-
urement of 25(OH)D in the UK over recent years, despite the
lack of clarity over which people to test and how to interpret
low levels. This is likely to be related to increased public
awareness of the prevalence of vitamin D deficiency, as well
as current debates about the extent of the role of vitamin D in
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disease. Good practice means that testing should only be per-
formed where the result of the test is aligned with current
clinical guidance, if it will change your clinical management
plan, and where you as the clinician are aware of how to
interpret the result correctly (Francis et al., 2018). See
Table 2 for recommendations on vitamin D testing to help
guide clinical decision making.
Differential diagnosis
When a person presents with symptoms and signs of rickets or
osteomalacia, it is important to be aware of other diseases that
could cause similar presentations, as this will help to guide
further investigation. Where bone pain and muscle weakness
are the predominant features, consider bone or soft tissue
cancer, myeloma, fibromyalgia, fracture, osteomyelitis,
Paget’s disease, parathyroid disease, polymyalgia rheumatica
and rheumatoid arthritis (NICE, 2018). Alternative causes of
painless muscle weakness include polymyositis, dermatomyo-
sitis, thyroid disease and muscular dystrophies (NICE, 2018).
Other blood tests
Appropriate use of blood tests, depending on the clinical
presentation, can help to secure a diagnosis. A bone profile
including adjusted calcium, phosphate, PTH and ALP will
assess for hypocalcaemia and markers of bone disease.
Renal, liver and thyroid function, full blood count and fer-
ritin, malabsorption screen, rheumatoid or other autoimmune
screening and inflammatory markers might also be appropri-
ate depending on the clinical history (NICE, 2018). In
children consider referring to local clinical guidance for spe-
cialist input.
How to interpret 25(OH)D and bone profile
National guidelines provide recommendations with regard to
the interpretation of vitamin D levels. For recommendations
see Table 3 for interpretation of vitamin D levels and Table 4
for bone profile.
Figure 2. Schematic representation that helps to define broad groups for clinical consideration and decision
making.
Reproduced with permission from the Royal Osteoporosis Society.
Table 2. Recommendations for vitamin D testing.
25(OH)D testing is
recommened
 Clinical symptoms or signs to suggest osteomalacia or rickets (Francis et al., 2018; NICE,
2018)
 People who are being treated with bisphosphonates or other antiresorptive drugs
(testing may not be required in people receiving vitamin D or combined calcium and
vitamin D supplements)




 Asymptomatic people without clinical risk factors (Francis et al., 2018; NICE, 2014)
 People with other diseases where testing is unlikely to influence clinical management




Consider referral to a specialist if there are features other than
dietary or lifestyle factors responsible for deficiency or the
person is pregnant (NICE, 2018). Some vitamin D supplements
are produced by irradiating sheep wool, whereas others do
not require the use of animal products. It is important when
considering vitamin D supplementation to ensure that the
product chosen is acceptable to people depending on their
religious and dietary backgrounds (Francis et al., 2018; NICE,
2018).
Oral vitamin D3 is the recommended preparation relating
to consistent concentrations and efficacy in raising serum
25(OH)D levels. Where the person is a strict vegan, vitamin
D2 is recommended, as this is not derived from animal sources
(UKMi, 2020). There is very limited evidence base to guide
dosing of vitamin D and several regimens can be used suc-
cessfully. In general, it is best to avoid giving large doses of
vitamin D, as this has been associated with an increased risk of
falls and fractures in older people for reasons that are incom-
pletely understood (Bischoff-Ferrari et al., 2016; Law et al.,
2006; Trajanoska and Rivadeneira, 2018).
Monitoring of treatment
Excessive oral intake of vitamin D can lead to toxic effects
such as hypercalcaemia (due to increased intestinal calcium
absorption and mobilisation of calcium from the bones),
which can then result in deposition of calcium in the soft tis-
sues, diffuse mineralisation of bones, and irreversible renal
and cardiovascular toxicity (SACN, 2016). Caution should be
exercised in people with poor renal function and those with
sarcoidosis and other granulomatous diseases where extra-
renal production of calciriol can occur leading to vitamin D
intoxication. The administration of vitamin treatment can also
unmask primary hyperparathyroidism. In these circumstances,
for both cases, it is important to be vigilant for potential fea-
tures of hypercalcaemia (NICE, 2018; Roger et al., 2018).
It is recommended that clinicians consult local prescribing
guidance with regard to the specific dose of vitamin D sup-
plementation, as there is many variations of preparation
schedule and practice should be specific to the local area.
Apart from these specific conditions, the risk of toxicity is
small, due to homeostatic mechanisms. Monitoring is not













PHPT " # $ " $ $/"
Osteomalacia # # $ " ## "
Paget’s $ $ $ $ $ "/""
CKD-MBD " # "" "" $ "
Osteoporosis $ $ $ $ $ $
PHPT – Primary hyperparathyroidism, CKD-MBD – Chronic kidney disease – metabolic bone disease.
" - elevated; ""- markedly elevated; #- reduced; $ within reference range.
Reproduced from Nairn C, Ralston SH (2020) Paget’s Disease of Bone: When and why to refer to specialist care. British Journal of General
Practice, 70(700): 561–562. with permission from the British Journal of General Practice.
Table 3. Interpretation of vitamin D level.
25(OH)D <25 nmol/L: Treat Prolonged deficiency significantly increases the risk of rickets in children
and osteomalacia in adults, as well as association with immunosuppression,
muscle weakness and potential increased risk of colon cancer (Firth et al.,
2020). It is recommended that all people in the UK should not fall below
25 nmol/L at any time in the year (SACN, 2016).
25(OH)D 25–50 nmol/L: Consider treatment
in those at risk of developing frank vitamin
D deficiency
 Malabsorption
 Ethnic groups/low sunlight exposure
 Prior to administration of bisphosphonates or other antiresorptive agents
25(OH)D >50 nmol/L: Reassure
Source: Firth et al. (2020) and Pilz et al. (2019).
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necessary in people started on low-dose vitamin D supple-
ments of up to 1600 units /day.
In people receiving treatment with higher doses for osteo-
malacia or rickets, it is customary to check serum calcium,
phosphate and ALP after 1 month and then 3–6 monthly
until values have returned to normal. Measurements of
25(OH)D and PTH may be considered after 6–12 months to
ensure that secondary hyperparathyroidism has been cor-
rected and vitamin D levels have increased.
Prevention
All people living in the UK aged 1 year and above should be
encouraged to take a daily supplement of 10 mg (400 IU) of
vitamin D all year, and 8.5–10mg (340–400 IU) daily in babies
aged up to 1 year (Chief Medical Officer, (CMO), 2017; NICE,
2018). However, evidence of the benefit of this supplementa-
tion has not yet been established.
Pregnant and breastfeeding women are eligible for free
vitamin supplementation through the UK-wide Healthy Start
scheme. People who are concerned about vitamin D defi-
ciency can be advised to buy over-the-counter supplementa-
tion and calculate calcium intake using on-line tools. Where
daily calcium intake is <700 mg/day, then offer dietary advice
to increase calcium intake or consider calcium supplementa-
tion if they are unable to make dietary changes. Where cal-
cium supplements have been initiated, check adjusted calcium
level a month after initiation (NICE, 2018).
Conclusion
Vitamin D deficiency is a common condition in the UK popu-
lation. In the majority of people this will be asymptomatic and
investigation is not required. Those people who develop
symptoms specific to vitamin D deficiency should be investi-
gated with treatment and monitoring initiated according to
national guidance. There is debate over potential implications
of vitamin D deficiency in non-skeletal disease, and as yet little
confirmatory evidence to suggest a causal relationship. It is of
great importance that GPs are aware of the current guidance
and debate surrounding vitamin D, as this is a common and
important issue for the UK population.
KEY POINTS
. Vitamin D deficiency is common in the UK and is mostly
commonly asymptomatic
. Severe and prolonged vitamin D deficiency may lead to
osteomalacia in adults or rickets in children
. There is no evidence as yet that vitamin D supplements
are effective in the prevention or treatment of other
medical conditions
. 25(OH)D is the recommended test to determine vitamin
D status, but it should only be used in specific clinical
circumstances
. National UK clinical guidance now recommends that all
people take a daily vitamin D supplement, but this is not
based on any evidence of benefit
. Treatment of osteomalacia and rickets should be
accompanied with monitoring of calcium, phosphate,
ALP, PTH and 25(OH)D levels. It is not necessary to
monitor people treated with low-dose vitamin D
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Duval GT, Brangier A, Barré J, et al. (2015) Vitamin D deficiency
and incident onset of orthostatic hypotension in older adults:
Preliminary results from the ‘MERE’ study. Journal of the
American Geriatrics Society 63(6): 1245–1247. DOI: 10.1111/
jgs.13504.
Firth JD, Conlon CP and Cox TM (2020). Oxford Textbook of
Medicine. Oxford: Oxford University Press.
Francis R, Aspray T, Fraser W, et al. (2018) Vitamin D and bone
health: A practical clinical guide for patient management.
Available at: https://strwebprdmedia.blob.core.windows.net/
media/ef2ideu2/ros-vitamin-d-and-bone-health-in-adults-febru-
ary-2020.pdf (accessed 22 July 2020).
Fraser W and Milan A (2013) Vitamin D assays: Past and present
debates, difficulties, and developments. Calcified Tissue
International 92(2): 118–127. DOI: 10.1007/s00223-012-9693-3.
Hatun S, Ozkan B, Orbak Z, et al. (2005) Vitamin D deficiency in
early infancy. Journal of Nutrition 135(2): 279–282. DOI:
10.1093/jn/135.2.279.
Hobson RP, Ralston S, Penman ID, et al. (2018). Davidson’s
Principles and Practice of Medicine. Edinburgh: Elsevier.
InnovAiT
667
Law M, Withers H, Morris J, et al. (2006) Vitamin D supplementation
and the prevention of fractures and falls: Results of a rando-
mised trial in elderly people in residential accommodation.
Age and Ageing. 35(5): 482–486. DOI: 10.1093/ageing/afj080.
Liu X, Baylin A and Levy PD (2018) Vitamin D deficiency and
insufficiency among US adults: Prevalence, predictors and clin-
ical implications. British Journal of Nutrition 119(8): 928–936.
DOI: 10.1017/S0007114518000491.
Macdonald HM, Mavroeidi A, Fraser WD, et al. (2011) Sunlight and
dietary contributions to the seasonal vitamin D status of cohorts
of healthy postmenopausal women living at northerly latitudes:
A major cause for concern?. Osteoporosis International 22(9):
2461–2472. DOI: 10.1007/s00198-010-1467-z.
Nairn C, Ralston SH, (2020). Paget s disease of bone: when and why
to refer to specialist care. British Journal of General Practice,
70(700): 561–562. DOI: 10.3399/bjgp20X713369.
NICE (2014) Vitamin D: Supplement use in specific population
groups. Available at: www.nice.org.uk/guidance/ph56
(accessed 27 April 2020).
NICE (2018) Clinical knowledge summary: Vitamin D deficiency in
adults – treatment and prevention. Available at: https://cks.ni-
ce.org.uk/vitamin-d-deficiency-in-adults-treatment-and-preven-
tion (accessed 27 April 2020).
Pearce S and Cheetham T (2010) Diagnosis and management of
vitamin D deficiency. British Medical Journal 340(7738): 142.
DOI: 10.1136/bmj.b5664.
Pereira-Santos M, Costa PRF, Assis AMO, et al. (2015) Obesity and
vitamin D deficiency: A systematic review and meta-analysis.
Obesity Reviews 16(4): 341–349. DOI: 10.1111/obr.12239.
Pilz S, Zittermann A, Trummer C, et al. (2019) Vitamin D testing and
treatment: A narrative review of current evidence. Endocrine
Connections 8(2): R27–R43. DOI: 10.1530/EC-18-0432.
Powe CE, Evans MK, Wenger J, et al. (2013) Vitamin D–binding
protein and vitamin D status of Black Americans and White
Americans. New England Journal of Medicine 369(21):
1991–2000. DOI: 10.1056/NEJMoa1306357.
Priemel M, von Domarus C, Klatte TO, et al. (2010) Bone mineral-
ization defects and vitamin D deficiency: Histomorphometric
analysis of iliac crest bone biopsies and circulating 25-hydroxy-
vitamin D in 675 patients. Journal of Bone and Mineral
Research 25(2): 305–312. DOI: 10.1359/jbmr.090728.
RCGP. Clinical topic guide: Population health: Promoting health
and preventing disease. Available at: www.rcgp.org.uk/train-
ing-exams/training/gp-curriculum-overview.aspx (accessed
13 July 2020).
Roger F, Aspray T, Fraser W, et al. (2018) Vitamin D and bone
health: A practical clinical guideline for patient
management.Available at: https://strwebprdmedia.blob.
core.windows.net/media/ef2ideu2/ros-vitamin-d-and-bone-
health-in-adults-february-2020.pdf (accessed 19 May 2020).
SACN (2016) Scientific Advisory Committee on Nutrition vitamin D
and health. Available at: https://assets.publishing.service.
gov.uk/government/uploads/system/uploads/attachment_
data/file/537616/SACN_Vitamin_D_and_Health_report.pdf
(accessed 27 April 2020).
Sievenpiper JL, McIntyre EA, Verrill M, et al. (2008) Unrecognised
severe vitamin D deficiency. BMJ 336(7657): 1371. DOI:
10.1136/bmj.39555.820394.BE.
Trajanoska K and Rivadeneira F (2018) Using Mendelian random-
ization to decipher mechanisms of bone disease. Current
Osteoporosis Reports 16(5): 531–540. DOI: 10.1007/s11914-018-
0467-3.
UKMi (2020) UK Medicines Information: What dose of vitamin D
should be prescribed for the treatment of vitamin D deficiency?
Available at: www.sps.nhs.uk/articles/what-dose-of-vitamin-d-
should-be-prescribed-for-the-treatment-of-vitamin-d-deficiency-
2/ (accessed 27 April 2020).
Wharton B and Bishop N (2003) Rickets. The Lancet 362(9393):
1389–1400. DOI: 10.1016/S0140-6736(03)14636-3.
DOI: 10.1177/1755738020952038c
AKT answer relating to cardiovascular disease in people
with intellectual disability
Answer A. Hypertension
There is a higher prevalence of cardiovascular disease in
those people with an intellectual disability. This is caused
by a number of different factors including an accelerated
ageing process, poor lifestyle choices including indulging
in cigarettes and alcohol, having a poor diet and lack of
adequate exercise. Hypertension is actually less common
in this population; however, it is usually under diagnosed.
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